摘要
目的:观察康柏西普治疗湿性老年性黄斑变性的效果。方法:选择2015年1月-2020年12月笔者所在医院收治的湿性老年性黄斑变性患者80例进行临床研究。所有患者均给予玻璃体腔内注射康柏西普治疗。注射前和每次注射后1个月设定为M0、M1、M2、M3,所有患者在各时间点接受常规眼科检查和频域光学相关断层扫描检查。观察不同时间点患者BCVA及黄斑中心凹视网膜厚度变化情况。观察治疗前后单纯视网膜下积液、单纯视网膜内积液及混合积液患者的BCVA变化情况。根据治疗3个月后积液是否消退进行分组,观察积液消退患者和未消退患者BCVA的差异。结果:与前一时间点相比,患者BCVA、黄斑中心凹视网膜厚度均明显降低,差异有统计学意义(P<0.05)。治疗后,单纯视网膜下积液、单纯视网膜内积液、混合积液患者BCVA均较治疗前明显降低(P<0.05);80例患者中治疗前49例存在视网膜内积液,治疗3个月后36例消退,13例未消退。治疗前,两组BCVA水平比较差异无统计学意义(P>0.05),治疗后,两组BCVA均较治疗前明显降低,差异有统计学意义(P<0.05),但两组治疗后BCVA水平比较差异无统计学意义(P>0.05)。80例患者中治疗前68例存在视网膜下积液,治疗3个月后50例消退,18例未消退。治疗前,两组BCVA水平比较差异无统计学意义(P>0.05),治疗后,两组BCVA水平均较治疗前明显降低,差异有统计学意义(P<0.05)。但两组治疗后比较差异无统计学意义(P>0.05)。结论:康柏西普治疗湿性老年性黄斑变性具有较好的效果,能够改善黄斑中心凹结构。
Objective:To observe the effect of Conbercept in the treatment of wet senile macular degeneration.Method:Eighty patients with wet senile macular degeneration from January 2015 to December 2020 in our hospital were selected for the clinical study.All patients were treated with intravitreal injection of Conbercept.M0,M1,M2 and M3 were set before and 1 month after each injection.All patients received routine ophthalmic examination and frequency domain optical correlation tomography at each time points.The changes of BCVA and retinal thickness in macular fovea at different time points were observed.The changes of BCVA in patients with simple retina subretinal effusion,simple intraretinal effusion and mixed effusion before and after treatment were observed.The patients were divided into groups according to whether the effusion subsided after 3 months of treatment,the difference of BCVA between the patients with effusion subsided and patients without effusion subsided was observed.Result:Compared with the previous time point,BCVA and macular fovea retinal thickness of patients were significantly reduced,the differences were statistically significant(P<0.05).After treatment,BCVA of patients with simple retina subretinal effusion,simple retina intraretinal effusion and mixed effusion were significantly reduced compared with those before treatment(P<0.05).Among the 80 patients,49 patients had retina intraretinal effusion before treatment,36 patients subsided after 3 months treatment,13 cases did not subside.Before treatment,there was no significant difference in BCVA level between the two groups(P>0.05).After treatment,the BCVA levels in both groups were significantly reduced compared with those before treatment,the differences were statistically significant(P<0.05),but there was no significant difference in BCVA levels between the two groups after treatment(P>0.05).Among the 80 patients,68 had retina subretinal effusion before treatment,50 patients subsided after 3 months treatment,and 18 did not subside.There was no significant difference in BCVA level between the two groups before treatment(P>0.05).After treatment,the BCVA levels in both groups were significantly reduced compared with those before treatment,the differences were statistically significant(P<0.05),but there was no significant difference in BCVA levels between the two groups after treatment(P>0.05).Conclusion:Conbercept has a good effect in the treatment of wet senile macular degeneration and can improve the structure of macular fovea.
作者
徐江姗
XU Jiangshan(Fangshan District First Hospital of Beijing,Beijing 102400,China)
出处
《中外医学研究》
2021年第26期97-99,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
湿性老年性黄斑变性
康柏西普
频域光学相干断层扫描
Wet senile macular degeneration
Conbercept
Frequency domain optical correlation tomography